99010-07-8

Basic information

• Product Name: 4-CHLORO-6-FLUORO-3-NITRO-QUINOLINE
• Synonyms: 4-CHLORO-6-FLUORO-3-NITRO-QUINOLINE;Quinoline, 4-chloro-6-fluoro-3-nitro-
• CAS NO: 99010-07-8
• Molecular Formula: C₉H₄ClFN₂O₂
• Molecular Weight: 226.59
• Mol File: 99010-07-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-CHLORO-6-FLUORO-3-NITRO-QUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6-FLUORO-3-NITRO-QUINOLINE(99010-07-8)
• EPA Substance Registry System: 4-CHLORO-6-FLUORO-3-NITRO-QUINOLINE(99010-07-8)

Safety Data

• Hazardous Substances Data: 99010-07-8(Hazardous Substances Data)

Upstream product

• 628284-75-3 6-fluoro-3-nitroquinolin-4-ol 

Downstream Products

• 628284-77-5 (6-fluoro-3-nitro-quinolin-4-yl)-(2-fluoro-phenyl)-amine 

Relevant articles and documents

CYCLIC SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES

The present invention provides novel cyclic substituted imidazo[4,5- c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof, wherein R1, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Synthesis and structure-activity relationships of fused imidazopyridines: A new series of benzodiazepine receptor ligands

2-Arylimidazo[4,5-c]quinolines and analogous fused imidazopyridines were synthesized and evaluated as benzodiazepine receptor ligands. Affinity to the receptors was greatly affected by the bulkiness of the aryl group at the 2- position, compared to the pyrazoloquinolines such as CGS-9896. Derivatives with an isoxazole moiety at the 2-position showed high binding affinity and in vivo activity. In the imidazo[4,5-c]quinoline series, substitution at the 6-position decreased or abolished activity. Most derivatives with an unsubstituted isoxazolyl group showed antagonist or inverse agonist activity except for the 7-halo analogues, which exhibited agonist activity. On the other hand, 5-methylisoxazol-3-yl or 3-methylisoxazol-5-yl derivatives generally exhibited agonist activity. A similar substitution effect on the isoxazole moiety was observed in the imidazopyridines fused with a nonaromatic ring. From the detailed pharmacological evaluation, S-8510, 2- (3-isoxazolyl)-3,6,7,9-tetrahydroimidazo[4,5-d]pyrano[4,3-b]pyridine monophosphate, possessing weak inverse agonist activity was selected as a therapeutic candidate for the treatment of some symptoms of senile dementia.